DexCom (NASDAQ:DXCM) Upgraded by Wall Street Zen to Buy Rating

DexCom (NASDAQ:DXCM - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Friday.

Several other equities analysts also recently weighed in on the company. Citigroup reaffirmed a "buy" rating and issued a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Robert W. Baird dropped their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Mizuho raised their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Barclays raised their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $99.60.

DexCom Stock Performance

Shares of DXCM stock traded down $0.21 during trading hours on Friday, reaching $83.89. 2,616,540 shares of the company's stock were exchanged, compared to its average volume of 4,433,622. DexCom has a 1 year low of $57.52 and a 1 year high of $113.28. The company has a market cap of $32.89 billion, a P/E ratio of 62.60, a price-to-earnings-growth ratio of 1.79 and a beta of 1.44. The company's 50 day moving average is $84.49 and its two-hundred day moving average is $80.17. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The business's revenue for the quarter was up 12.5% on a year-over-year basis. Equities research analysts anticipate that DexCom will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president owned 95,602 shares in the company, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,190 shares of company stock worth $2,281,732. Company insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DXCM. Brighton Jones LLC lifted its stake in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG increased its holdings in DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after buying an additional 2,010 shares during the last quarter. Avantax Advisory Services Inc. increased its holdings in DexCom by 34.4% in the fourth quarter. Avantax Advisory Services Inc. now owns 7,184 shares of the medical device company's stock valued at $559,000 after buying an additional 1,840 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in DexCom by 30.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 16,159 shares of the medical device company's stock valued at $1,257,000 after buying an additional 3,778 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in shares of DexCom by 30.3% during the fourth quarter. Signaturefd LLC now owns 6,561 shares of the medical device company's stock valued at $510,000 after purchasing an additional 1,526 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.